


## PHARMACEUTICAL 2018

## RespireRx Pharmaceuticals Inc. Rank 327 of 349





## PHARMACEUTICAL 2018

## RespireRx Pharmaceuticals Inc. Rank 327 of 349

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1,924% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 472% points.

The company's Economic Capital Ratio, given in the ranking table, is -936%, being 659% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	177
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,550
Liabilities, Non-Current	0
Other Assets	18
Other Compr. Net Income	0
Other Expenses	102
Other Liabilities	0
Other Net Income	58
Property and Equipment	0
Research and Development	1,732
Revenues	0
Selling, General and Administrative Expense	2,516

Output Variable	Value in 1000 USD
Assets	195
Liabilities	4,550
Expenses	4,350
Stockholders Equity	-4,355
Net Income	-4,291
Comprehensive Net Income	-4,291
Economic Capital Ratio	-936%